JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

Kodu・Aktsiate loetelu・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Suletud

SektorTervishoid

6.59 -1.79

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

6.54

Max

6.6

Põhinäitajad
By Trading Economics
Sissetulek	7.8M 13M
Müük	-4M 159M
Kasumimarginaal	8.092
Töötajad	580
EBITDA	3.7M 32M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+199.39% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	23. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-93M 1.4B
Eelmine avamishind	8.38
Eelmine sulgemishind	6.59

Uudiste sentiment

By Acuity

72%

28%

315 / 352 Pingereas Healthcare

BioCryst Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. veebr 2026, 23:59 UTC

Market Talk

Oil Prices Fall Amid Signs of U.S.-Iran Negotiations -- Market Talk

1. veebr 2026, 23:47 UTC

Market Talk

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

1. veebr 2026, 23:44 UTC

Market Talk

Gold Falls as Markets Further Price in Warsh-Led Fed -- Market Talk

1. veebr 2026, 12:47 UTC

Omandamised, ülevõtmised, äriostud

KKR-Led Group Set to Buy Singapore Data-Center Firm Valued at Over $10 Billion -- Update

1. veebr 2026, 03:02 UTC

Omandamised, ülevõtmised, äriostud

KKR-Led Group Set to Buy Singapore Data-Center Firm Valued at Over $10 Billion

1. veebr 2026, 03:01 UTC

Omandamised, ülevõtmised, äriostud

KKR Consortium Currently Owns Near 20% Stake in STT GDC

1. veebr 2026, 03:01 UTC

Omandamised, ülevõtmised, äriostud

KKR Consortium Acquiring Remaining Stake in STT GDC With Singtel, Sources Say

31. jaan 2026, 18:48 UTC

Omandamised, ülevõtmised, äriostud

Negotiations Over $100B OpenAI, Nvidia Deal Stall -- Update

31. jaan 2026, 16:40 UTC

Tulu

'All Boats Are Rising' in Data and Memory, Says Western Digital's CFO. Just Look at the Stocks. -- Barrons.com

31. jaan 2026, 09:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Negotiations Over $100B OpenAI, Nvidia Deal Stall -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Nvidia, OpenAI in Talks to Revise Nature of Broader Partnership, Sources Say -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Nvidia CEO Jensen Huang Has Privately Told Colleagues That Deal Is Non-Binding, Sources Say -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Nvidia's Huang Has Privately Criticized OpenAI's Business Strategy, Sources Say -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

OpenAI, Nvidia Deal Talks Stalled in Recent Months, Sources Say -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Nvidia's Huang Expressed Concerns Over Competition OpenAI Faces From Anthropic, Google, Sources Say -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Nvidia Weighing Equity Investment of Tens of Billions of Dollars Into OpenAI, Sources Say -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Negotiations Over $100B OpenAI, Nvidia Deal Stall, Sources Say -- WSJ

30. jaan 2026, 23:41 UTC

Market Talk

Deckers Outdoor Seen as Undervalued -- Market Talk

30. jaan 2026, 23:12 UTC

Omandamised, ülevõtmised, äriostud

Supreme Court of British Columbia Approves Fortescue Purchase of Alta Copper

30. jaan 2026, 22:20 UTC

Tulu

Verizon Posts Strong Subscriber Gains Under New CEO -- WSJ

30. jaan 2026, 22:10 UTC

Market Talk

Disney CEO's Exit Plan Marks Abrupt End to Messy Succession -- Market Talk

30. jaan 2026, 21:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

30. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30. jaan 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

30. jaan 2026, 21:42 UTC

Tulu

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30. jaan 2026, 21:36 UTC

Tulu

GE Aerospace and GE Vernova Issue Their Annual Reports. They Contain Messages for Investors. -- Barrons.com

30. jaan 2026, 21:33 UTC

Tulu

Tesla Stock Rebounds From Earnings Dip. SpaceX Is Helping. -- Barrons.com

30. jaan 2026, 20:42 UTC

Tulu

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30. jaan 2026, 20:37 UTC

Omandamised, ülevõtmised, äriostud

Why a Ruling Over CK Hutchison's Panama Canal Ports Matters -- and What's Next -- WSJ

Võrdlus sarnastega

Hinnamuutus

BioCryst Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

199.39% tõus

12 kuu keskmine prognoos

Keskmine 19.7 USD 199.39%

Kõrge 32 USD

Madal 8 USD

Põhineb 10 Wall Streeti analüütiku instrumendi BioCryst Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi BioCryst Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

315 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.